Literature DB >> 11707811

Clinicopathological correlates of IgM paraproteinemias.

R G Owen1, L A Parapia, J Higginson, S A Misbah, J A Child, G J Morgan, A S Jack.   

Abstract

IgM paraproteinemia is considered to be the major defining feature of Waldenström's macroglobulinemia (WM), but it may also occur in other B-cell lymphoproliferative disorders. In this study we have reviewed the final pathological diagnosis of 106 patients with IgM paraproteinemia investigated in our laboratories between April 1993 and May 1999. In 22 of the 106 patients (20.8%), there was no clinical or laboratory evidence of an underlying lymphoproliferative disorder, and a diagnosis of monoclonal gammopathy of undetermined significance (MGUS) was therefore made. In 60 cases (56.6%), a diagnosis of WM was made, while in the remaining 24 patients, the final diagnosis was chronic lymphocytic leukemia (n = 10), diffuse large B-cell lymphoma (n = 5), extranodal marginal-zone lymphoma (n = 3), follicular lymphoma (n = 3), and mantle-cell lymphoma (n = 3). The median paraprotein concentration in patients with WM, MGUS, and "other" lymphoproliferative disorders was 13 g/L (range, 2-54), 6 g/L (range, 3-30), and 4.5 g/L (range, 3-61), respectively. It is clear that IgM paraproteins are demonstrable in all subtypes of peripheral B-cell disorders and, although paraprotein concentrations are generally higher in WM, there is considerable overlap. Immunophenotypic criteria are therefore essential for the accurate diagnosis of WM.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11707811     DOI: 10.3816/clm.2000.n.003

Source DB:  PubMed          Journal:  Clin Lymphoma        ISSN: 1526-9655


  7 in total

1.  Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families.

Authors:  Mary L McMaster; Lynn R Goldin; Yan Bai; Monica Ter-Minassian; Stefan Boehringer; Therese R Giambarresi; Linda G Vasquez; Margaret A Tucker
Journal:  Am J Hum Genet       Date:  2006-08-31       Impact factor: 11.025

2.  IgM Myeloma or Waldenstrom's Macroglobulinemia Is the Big Question?

Authors:  Vijaya Raj Bhatt; Srujitha Murukutla; Muniba Naqi; Shradha Pant; Shiksha Kedia; Terenig Terjanian
Journal:  Maedica (Buchar)       Date:  2014-03

3.  Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice.

Authors:  Pieter Van Vlierberghe; Steven Goossens; Tim Pieters; Sara T'Sas; Stijn Vanhee; André Almeida; Yasmine Driege; Juliette Roels; Wouter Van Loocke; Willem Daneels; Mathijs Baens; Arnaud Marchand; Maaike Van Trimpont; Filip Matthijssens; Julie Morscio; Kelly Lemeire; Béatrice Lintermans; Lindy Reunes; Patrick Chaltin; Fritz Offner; Jo Van Dorpe; Tino Hochepied; Geert Berx; Rudi Beyaert; Jens Staal
Journal:  J Exp Med       Date:  2021-08-18       Impact factor: 14.307

Review 4.  The classification of lymphomas: a new beginning or the end of an era?

Authors:  A S Jack
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

5.  IgM multiple myeloma: a diagnostic challenge in a patient with coexisting chronic lymphocytic leukaemia.

Authors:  Saman Hewamana; Chris Pepper; Steve Couzens; Alun Thomas; Steven Knapper
Journal:  Int J Hematol       Date:  2008-10-11       Impact factor: 2.490

6.  Waldenstrom's macroglobulinemia presenting with lytic bone lesions: a rare presentation.

Authors:  Mukta Pujani; Shivani Kushwaha; Neha Sethi; Anu Beniwal; Shailaja Shukla
Journal:  Blood Res       Date:  2013-09-25

7.  High-grade nodal marginal zone lymphoma with diffuse bone marrow involvement and IgM-type monoclonal paraproteinemia: a case report and review of the literature.

Authors:  Sang Hyuk Park; Jaewook Kim; Joseph Jeong; Seon-Ho Lee; Hee Jeong Cha; Seol Hoon Park; Yunsuk Choi; Jae-Cheol Jo; Ji-Hun Lim
Journal:  Blood Res       Date:  2019-09-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.